Indian Cardiovascular Drug Exports to the US Surge 138% to $3.7 Billion

India's cardiovascular drug exports to the United States more than doubled in 2025, jumping 138% from $1.55 billion to $3.7 billion. The surge propelled India to a 27.5% share of America's $13.4 billion cardiovascular import market — second only to Switzerland at $4.4 billion — and underscores the deepening dependence of the world's largest healthcare system on Indian pharmaceutical manufacturing.

A $2.1 Billion Leap in a Single Year

The scale of the increase is striking. India added $2.15 billion in cardiovascular drug exports to the US in just twelve months — more than the entire cardiovascular export total of third-ranked France ($1.28 billion) or fourth-ranked United Kingdom ($1.26 billion). This was not gradual expansion; it was a step-change that reshaped the competitive landscape.

Total US cardiovascular drug imports grew 31.4% year-over-year, from $10.2 billion in 2024 to $13.4 billion in 2025. India's growth rate of 138% far outpaced the market, meaning Indian manufacturers captured a disproportionate share of the expansion.

Closing the Gap with Switzerland

Switzerland remains the top supplier at $4.4 billion, anchored by the global headquarters of Novartis and Roche. But the gap has narrowed dramatically. In 2024, Switzerland led India by roughly $2.9 billion; by 2025, the lead had shrunk to just $710 million. If current trajectories hold, India could overtake Switzerland as the leading supplier of cardiovascular drugs to the American market within two years.

Germany ($1.13 billion), Slovenia ($580 million), and Ireland ($448 million) round out the top six — all well behind the two leaders. China, despite its growing pharmaceutical ambitions, contributed just $149 million.

What Is Driving the Surge

Several forces converge behind the numbers. First, patent expirations on major cardiovascular brands have opened the door for generic manufacturers. The FDA approved a record number of generic cardiovascular drug applications in 2024 and 2025, and Indian companies — which collectively hold approximately 40% of all abbreviated new drug applications (ANDAs) approved by the FDA — were positioned to capitalise.

Second, the broader trend toward affordable medicine continues to intensify. According to the Association for Accessible Medicines, generic and biosimilar medicines saved the US healthcare system $373 billion in 2023 alone. Cardiovascular disease remains the leading cause of death in the United States, affecting roughly 128 million Americans, which makes cost-effective treatment a policy imperative.

Third, India's pharmaceutical sector has invested heavily in US regulatory compliance. The country now hosts the largest number of FDA-approved manufacturing facilities outside the United States. This regulatory infrastructure reduces approval timelines and builds buyer confidence among US pharmacy benefit managers and hospital systems.

India's Broader Pharma Footprint

Cardiovascular drugs are the brightest spot in a broader growth story. India's total pharmaceutical exports to the US (chapters 29 and 30 combined) reached $19.1 billion in 2025, up from $16.0 billion in 2024 — a 19.8% increase. Cardiovascular medicaments alone accounted for 19.4% of this total, making it the single largest product category.

Other high-growth categories include analgesics and anti-inflammatory agents ($1.31 billion, up 118%), ibuprofen-based formulations ($532 million, up 113%), and heterocyclic compounds used as active pharmaceutical ingredients ($404 million, up 113%). The pattern is clear: Indian manufacturers are gaining ground across the entire pharmaceutical value chain, from raw intermediates to finished dosage forms.

What This Means for Indian Exporters

The cardiovascular segment offers Indian pharmaceutical companies a rare combination: massive market size, strong growth momentum, and structural tailwinds from patent cliffs and cost pressure. For companies not yet exporting cardiovascular products to the US, the data makes a compelling case for investment in ANDA filings and FDA-compliant manufacturing capacity.

The strategic opportunity extends beyond volume. As India approaches parity with Switzerland in cardiovascular supply, it gains negotiating leverage with US payers and distributors. Companies that combine regulatory quality with competitive pricing will be positioned to capture not just generics volume but also the emerging biosimilar cardiovascular market — a segment projected to grow significantly as biologic patents expire.

India's 138% surge in cardiovascular drug exports to the US is more than a trade statistic. It marks the moment when Indian pharma moved from a supporting role to a leading one in America's most critical therapeutic category.